What is the vesting schedule and exercise price of the inducement grant, and how might that influence future selling pressure?

Vesting schedule & exercise price – what we know:

The press release only states that Aligos granted non‑qualified stock options for 42,300 shares to new hires on Aug. 12, 2025. Neither the exact vesting timetable nor the grant‑date exercise price was disclosed in the filing. In practice, Nasdaq‑listed biotech firms typically structure inducement awards with a one‑year “cliff” followed by monthly or quarterly vesting over a total of three to four years, and they set the strike price at or near the closing price of the stock on the grant date (often within 5 % of that level). Until the company files a Form 8‑K or a detailed proxy statement, those assumptions remain the most reasonable baseline.

Potential impact on future selling pressure:

Assuming a standard 3‑year vesting curve and a strike at today’s market price (~$ X per share), the options will not become exercisable for at least a year, limiting immediate dilution. However, when the first tranche vests, employees may exercise and promptly sell to cover taxes, creating a modest, predictable uptick in supply. If the stock rallies beyond the strike price, the incentive to hold increases, muting sell‑offs; conversely, a flat or declining price could trigger “cash‑out” selling at each vesting date, adding periodic pressure. Traders should watch the company’s upcoming SEC filings for the exact vesting terms, and consider setting modest sell‑stop orders around the expected vesting dates (e.g., Q4 2026) to hedge against short‑term liquidity spikes. In the meantime, the absence of an immediate dilution event keeps the current technical outlook (e.g., support at the 200‑day MA) largely intact, but a watchful eye on volume spikes around the anticipated vesting calendar is prudent.